

Helix BioMedix Announces the Launch of DermaVentures' P.A.C. Perfect Product Line Through Joint Venture

-First Acne Product Line Focused on Rich Skin Tones-

Dec 14, 2007 - Bothell, Washington

Helix BioMedix, Inc. (OTCBB: HXBM - News), a developer of bioactive peptides, today announced the launch of the P.A.C. Perfect™ (Peptide-powered Acne Control) product line through a joint venture with DermaVentures™, LLC, an alliance of some of the skincare industry's leading innovators.

P.A.C. Perfect, a comprehensive skin health system using RadianceGuard-64™, was launched into a test-marketing phase on November 20, 2007. The initial marketing efforts include an infomercial broadcast through Spanish speaking television media supported by a website (www.DermaVentures.com). Initial response has been strong with over 80 percent of the customers opting to purchase multiple kits or enroll in a continuity program resulting in additional purchases. The financial benefits associated with these new products will be initially recognized in Helix BioMedix's first quarter 2008 financial results.

"We are pleased with the launch of the P.A.C. Perfect product, which was one of our key strategic objectives announced at the beginning of 2007," commented R. Stephen Beatty, President and Chief Executive Officer of Helix BioMedix. "We are encouraged by the initial response to the product and believe that our partnership with DermaVentures will prove to be a key contributor towards our revenue goals for 2008 and beyond."

Ralph Katz, a Principal of DermaVentures stated, "We are excited about the launch of P.A.C. Perfect, which is the first of several planned skin care products in a platform of dermatology solutions. We believe that Helix BioMedix has a strong product development pipeline, which enabled us to create an innovative product in a relatively short time. As part of our efforts to build the P.A.C Perfect brand, we will attempt a more aggressive marketing campaign next year that will build upon our early infomercial success."

The P.A.C. Perfect System is designed specifically for the needs of richer skin tones suffering from acne. The 3-step system includes a 'Treatment Essence' with active anti-acne medication and the breakthrough technology of RadianceGuard-64™ to combat breakouts, reduce redness, even skin tone and leave skin clear and radiant. The Treatment Essence is supported by a 'Nighttime Recovery Lotion' formulated with powerful anti-oxidants that enhance skin resiliency and restore moisture balance. Finally, the dual performance 'Toning Cleanser' treats acne as it washes away oil and impurities and tones skin while leaving the skin feeling and looking smooth and polished.

For more information regarding P.A.C. Perfect, or to place an order, please either visit www.dermaventures.com or www.PACPerfectskin.com or call 800 901 5381.

About Helix BioMedix, Inc.

Helix BioMedix, Inc. is a biopharmaceutical company with an extensive library of diverse bioactive peptides and patents covering six distinct classes and hundreds of thousands of peptide sequences. Our mission is to enrich clinical practice and the patient/consumer experience by developing topically-applied products which

offer the health, beauty and safety benefits of our advanced bioactive small molecule technology. Our vision is to be recognized as the world leader in the identification, qualification and commercialization of natural and synthetic peptides.

Our core competencies include peptide design, synthesis and characterization together with assay development, screening, tissue culture and microbiology, leveraged through relationships with contract research organizations and peptide manufacturers. We have the capability to take our product development programs from theoretical concept to a validated and qualified skin care active ingredient fully validated as to efficacy and safety. Applications for Helix BioMedix peptides include anti-aging cosmeceutical skin care and acne treatment as well as other topical anti-infective pharmaceuticals and wound healing applications. In addition, we are developing finished, peptide-based products to market with our partners.

More information about the company and its proprietary peptides may be found on the company's website at www.helixbiomedix.com.

Forward Looking Statements

This press release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding activities, events or developments that the company expects, believes or anticipates may occur in the future, including statements related to its potential growth, product development and commercialization and revenue. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the company's ability to successfully raise additional capital, enter into revenue generating license agreements, continue its research and development efforts, including pre-clinical and clinical studies, continue developing marketable peptide-based products and general economic conditions. Additional assumptions, risks and uncertainties are described in detail in the company's reports and other filings with the Securities and Exchange Commission. Such filings are available on the company's website or at www.sec.gov. Readers are cautioned that such forward-looking statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances.

Helix BioMedix Contacts:

Investor Contact:

Ryan Bright
Shelton Group Investor Relations
972-239-5119 X 159
rbright@sheltongroup.com

Company Contact:

R. Stephen Beatty
President and CEO
425-402-8400
sbeatty@helixbiomedix.com

Source: Helix BioMedix, Inc.

